Diligence memo · auto-generated · as of July 3, 2026
X-Biotix Therapeutics, Inc.
X-Biotix Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
X-Biotix Therapeutics, Inc. operates in Biotechnology, based in Waltham.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
X-Biotix Therapeutics, Inc. has raised $13M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.4M on 2018-04-17.
Most recent recorded round closed around 2019-11-12.
Valuation (modeled)modeled
Provath models X-Biotix Therapeutics, Inc. at approximately $145M (range $4.4M–$788M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 6.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 61% of Biotechnology peers (4293 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.